AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
June 23, 2022
-
April 29, 2022
-
April 14, 2022
-
March 11, 2022-Companies will research, develop and commercialize novel dopamine receptor modulators for potential treatment of neuropsychiatric conditions
-
March 10, 2022- Pivotal Phase 3 study evaluating atogepant in adult patients with chronic migraine meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo across the 12-week treatment period¹
-
March 01, 2022- Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
-
February 28, 2022- cGVHD is a life-threatening and rare condition that currently does not have an approved treatment for children under 12 and can occur in patients after receiving peripheral blood or bone marrow stem cell transplantation
-
February 24, 2022- In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to severe Crohn's disease treated with upadacitinib (45 mg once daily for induction) achieved both primary endpoints of clinical remission[a,b] and endoscopic response[c], compared to placebo at week 12[1]
-
February 22, 2022- Submission is based on clinical trial results that include findings showing clinically and statistically significant improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients with major depressive disorder (MDD) treated with cariprazine (VRAYLAR®) and an antidepressant
-
February 17, 2022
-
February 08, 2022JUVÉDERM® VOLBELLA® XC, PART OF THE NUMBER ONE CHOSEN COLLECTION OF FILLERS, IS THE FIRST AND ONLY DERMAL FILLER TO RECEIVE FDA APPROVAL FOR THE IMPROVEMENT OF INFRAORBITAL HOLLOWS[1,2]
-
February 02, 2022- Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent; Adjusted Diluted EPS of $12.70, an Increase of 20.3 Percent
-
February 01, 2022- A total of 26 abstracts, including 16 oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance standards of care for IBD patients
-
January 24, 2022SHARE YOUR BOTOX® COSMETIC STORY FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN
-
January 21, 2022- SKYRIZI® (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo[1,2,3]
-
January 14, 2022- Approval of two dose strengths (15 mg and 30 mg) supported by efficacy and safety data from one of the largest registrational Phase 3 programs in atopic dermatitis, with more than 2,500 patients evaluated across three studies[1]
-
January 07, 2022- Submissions supported by Phase 3 study in which upadacitinib (RINVOQ®) demonstrated significant improvements in signs and symptoms as well as physical function and disease activity versus placebo
-
January 04, 2022- Teliso-V, an investigational antibody-drug conjugate (ADC), is being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression
-
December 16, 2021-- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite --
-
December 14, 2021- Approval backed by two Phase 3 clinical studies where RINVOQ (15 mg, once daily) showed efficacy across multiple measures of disease activity in active psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis (RA) [1]
-
December 09, 2021- Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects and affects nearly half of the U.S. adult population, usually over age 40
-
December 06, 2021- In U-EXCEED, a significantly higher proportion of patients with moderate to severe Crohn's disease treated with upadacitinib (45 mg once daily for induction) achieved both primary endpoints of clinical remission[a,b] and endoscopic response[c] compared to placebo at week 12[1]
-
November 30, 2021- Submission supported by three pivotal Phase 3 studies in which risankizumab demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1,2]
-
November 23, 2021
-
November 23, 2021
-
November 18, 2021- A new literature review published in Advances in Therapy reported that for patients with rheumatoid arthritis (RA), achieving remission was associated with medical cost savings compared with other disease activity levels
-
November 17, 2021- Approval supported by data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2[1-3]
-
November 15, 2021POWERED BY ALLĒ, CONSUMERS ARE ENCOURAGED TO SHARE BOTOX COSMETIC BOGO EXCITEMENT WITH FRIENDS AND FAMILY
-
November 10, 2021
-
November 09, 2021- Post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials show people with active psoriatic arthritis (PsA) demonstrated greater clinical responses related to axial involvement when treated with upadacitinib (RINVOQ®) compared to placebo at week 24[1]
-
November 05, 2021- The 24-week integrated results from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluated the efficacy and safety of risankizumab (SKYRIZI®) versus placebo for the treatment of active psoriatic arthritis (PsA)¹
-
November 04, 2021- Nearly 30 abstracts on five investigational and approved medicines across eight cancer types to be presented at the 63rd ASH Annual Congress
-
November 01, 2021- Thirty-eight abstracts underscore AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases
-
October 29, 2021- Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects, affecting most adults over the age 40
-
October 29, 2021- In a Phase 3 clinical trial, Study 3111-301-001, cariprazine (VRAYLAR®) met its primary endpoint demonstrating statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score in patients with major depressive disorder
-
October 29, 2021- Reports Third-Quarter Diluted EPS of $1.78 on a GAAP Basis, an Increase of 38.0 Percent; Adjusted Diluted EPS of $3.33, an Increase of 17.7 Percent
-
October 28, 2021-- The pivotal Phase 3, randomized, double-blind, double-dummy, active-controlled study of continuous, subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in patients with advanced Parkinson's disease met its primary endpoint in a 12-week study
-
October 26, 2021- Detailed analyses to showcase visual outcomes and patient experience
-
October 15, 2021- CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2]
-
October 11, 2021THE POWER OF YOU CAMPAIGN ADVOCATES FOR AWARENESS AND EMPOWERS CONFIDENCE
-
October 07, 2021- In Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial, upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 23 percent)[1]
-
October 07, 2021- In Study 1 of the Phase 3 SELECT-AXIS 2 clinical trial, RINVOQ® (upadacitinib) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 18 percent) in patients with ankylosing spondylitis and inadequate response to bDMARD therapy[1]
-
October 05, 2021
-
September 30, 2021- Analyses include long-term efficacy and safety data from the open-label extension period of KEEPsAKE-1 and KEEPsAKE-2 evaluating risankizumab in psoriatic arthritis[1]
-
September 30, 2021- New RINVOQ (upadacitinib) analysis from the pivotal Phase 3 atopic dermatitis clinical program shows consistent EASI 75 rates for RINVOQ across key baseline characteristics of adults and adolescents with moderate to severe atopic dermatitis at week 16[1]
-
September 28, 2021- QULIPTA demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4¹
-
September 23, 2021- New analyses will highlight head-to-head trial evaluating safety and efficacy of RINVOQ® (upadacitinib) versus dupilumab in specific body regions of patients with moderate to severe atopic dermatitis
-
September 20, 2021- In three pivotal Phase 3 studies, risankizumab-rzaa demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1],[2],[3]
-
September 16, 2021- Significantly more upadacitinib patients achieved the primary and all secondary endpoints compared to placebo in Phase 3 induction and maintenance studies supporting the submissions[1-3]
-
September 13, 2021- AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise
-
September 10, 2021
-
September 10, 2021--Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson's disease
-
September 09, 2021
-
September 09, 2021- Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) published in The Lancet
-
September 08, 2021--Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine
-
August 24, 2021- Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1]
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
